Sixth Agreement to Amend the Floating Rate



 EXHIBIT 10.1 
 SIXTH AGREEMENT TO AMEND THE FLOATING RATE NOTE SUPPORT AGREEMENT 
 THIS SIXTH AMENDMENT is made as of this 22nd day of February, 2011. 
 WHEREAS, (a) Angiotech Pharmaceuticals, Inc.
(“Angiotech”), (b) the entities listed in Schedule A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto,
each Consenting Noteholder being a holder of and/or investment advisor or manager with investment discretion over Floating Rate Notes, executed a Floating Rate Note Support Agreement dated as of October 29, 2010 concerning the principal aspects
of an Exchange of Floating Rate Notes (as amended by an Agreement to Amend the Floating Rate Note Support Agreement dated November 29, 2010, a Second Agreement to Amend the Floating Rate Note Support Agreement dated December 15, 2010, a
Third Agreement to Amend the Floating Rate Note Support Agreement dated January 11, 2011, a Fourth Agreement to Amend the Floating Rate Note Support Agreement dated January 27, 2011 and a Fifth Agreement to Amend the Floating Rate Note
Support Agreement dated February 7, 2011, the “Support Agreement”); and 
 WHEREAS, the Consenting
Noteholders party to this sixth amendment (the “Sixth Amendment”) wish to further amend the Support Agreement in the manner set out in this Sixth Amendment; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Companies and the Consenting Noteholders party hereto hereby agree as follows:

  

	1.	Capitalized Terms 


Capitalized Terms that are used but not otherwise defined herein shall have the meanings ascribed thereto in the Support Agreement.

  

	2.	Consenting Noteholders Party to this Sixth Amendment 

 Each Consenting Noteholder party to this Sixth Amendment hereby represents and warrants, severally and not jointly, to each of the other parties to this Sixth Amendment (and acknowledges that each of the
other parties to this Sixth Amendment is relying upon such representations and warranties) that as of the date hereof: (a) it either (i) is the sole legal and beneficial owner of the principal amount of Floating Rate Notes disclosed to
Houlihan Lokey as of such date, or (ii) has the investment and voting discretion with respect to the principal amount of Floating Rate Notes disclosed to Houlihan Lokey as of such date; (b) it has the power and authority to bind the
beneficial owner(s) of such Floating Rate Notes to the terms of this Sixth Amendment; and (c) it has authorized and instructed Houlihan Lokey to advise Angiotech, in writing, of the aggregate amount of Floating Rate Notes held by the Consenting
Noteholders that are party to this Sixth Amendment. 
  

	3.	Amendments to the Support Agreement 

 The Support Agreement is hereby amended as follows: 








  
 - 2 -



	 	A.	Section 1(a) is amended by adding the following: 

  

	 	(vii)	the second subsection (1) in the definition of “Asset Sale” in the FRN Indenture shall be deleted and replaced with the following in the New FRN
Indenture: 

 “(i) any single transaction or series of related transactions that involves assets having a
Fair Market Value of less than $1.0 million or (ii) any transaction described in a schedule to this Indenture, provided, however, that the transactions described in the foregoing clauses (i) and (ii) shall not be deemed an Asset Sale
(and the Net Proceeds from such transactions not subject to Section 3.11 and Section 4.10 hereof) only to extent that the Net Proceeds resulting from such transactions are less than $10.0 million in the aggregate;” 

 

	 	(viii)	subsection (6) in the definition of “Asset Sale” in the FRN Indenture shall be deleted and replaced with the following in the New FRN Indenture:


 “the license of any intellectual property of the Company or any of its Restricted Subsidiaries in the
ordinary course of business that is not material to the Company or any of its Restricted Subsidiaries (as applicable), taken as a whole, up to an aggregate Fair Market Value of $5.0 million for all such transactions;” 

 

	 	(ix)	the following shall be added as subsection (11) in the definition of “Asset Sale” in the New FRN Indenture: 


“any single transaction or series of related transactions involving the sale of assets, where the Net Proceeds resulting from such
transactions does not cause the Company and its Restricted Subsidiaries to have consummated Asset Sales, measured from the date hereof, not otherwise excluded by the exclusions in (1) through (10) above, resulting in aggregate Net Proceeds
greater than $10.0 million (the “First Asset Sale Threshold”); provided, however, that, upon the aggregate Net Proceeds resulting from all such sales of assets, measured from the date hereof, exceeding the First Asset Sale
Threshold, the amount of the aggregate Net Proceeds which is less than the First Asset Sale Threshold shall continue to be deemed not subject to Section 3.11 and Section 4.10 hereof;” 

 

	 	(x)	the definition of “LIBOR” in the FRN Indenture shall be amended by adding the following language to the end of the definition in the New FRN Indenture:


 “Notwithstanding the foregoing, if at any time the LIBOR rate as so determined is less than 1.25%, the
LIBOR rate shall be deemed to be 1.25%.” 
  

	 	(xi)	the following language shall be added at the end of the definition of “Net Proceeds” in the New FRN Indenture: 









  
 - 3 -


 “and includes any payment to former shareholders of Quill in respect of any sale of
Quill related assets pursuant to a settlement agreement dated January 27, 2011.” 
  

	 	(xii)	the second paragraph of Section 4.10 of the FRN Indenture shall be deleted and replaced with the following in the New FRN Indenture: 


“Within 180 days after the receipt of any Net Proceeds from an Asset Sale, the Net Proceeds resulting from which causes the Company
and its Restricted Subsidiaries to have consummated Asset Sales, measured from the date hereof, resulting in aggregate Net Proceeds less than $25.0 million (the “Second Asset Sale Threshold”), the Company (or the applicable
Restricted Subsidiary, as the case may be) may apply such Net Proceeds at its option: 
  

	 	(1)	to repay Indebtedness and other Obligations under a Credit Facility (but only in the event that such Indebtedness is pari passu or senior in right of payment to
the Notes) and to correspondingly reduce commitments with respect thereto; 

  

	 	(2)	to acquire Business Assets, if, after giving effect to any such acquisition of Business Assets, such Business Assets become part of or held or owned by a Guarantor;


  

	 	(3)	to make a capital expenditure; or 

  

	 	(4)	to acquire other assets that are not classified as current assets under GAAP and that are used or useful in a Permitted Business; 


provided, however, that, in the event the Net Proceeds resulting from an Asset Sale causes the aggregate Net Proceeds for all Asset Sales
by the Company and its Restricted Subsidiaries, measured from the date hereof, to exceed the Second Asset Sale Threshold, the amount of the aggregate Net Proceeds which is less than the Second Asset Sale Threshold shall continue to be subject to
this paragraph.” 
  

	 	(xiii)	the fourth paragraph of Section 4.10 of the FRN Indenture shall be deleted and replaced with the following in the New FRN Indenture: 


“Any Net Proceeds from (i) Asset Sales that are not applied or invested as provided in the second paragraph of this
Section 4.10 or (ii) Asset Sales the Net Proceeds resulting from which cause the Company and its restricted Subsidiaries to have consummated Asset Sales, measured from the date hereof, resulting in Net Proceeds greater than the Second
Asset Sale Threshold, where such Net Proceeds are not applied to repay Indebtedness and reduce commitments as contemplated by Subsection (1) in the second paragraph of this Section 4.10 (except for Net Proceeds subject to the fifth
paragraph of this Section 4.10) will constitute “Excess Proceeds.” When the aggregate amount of Excess Proceeds exceeds $5.0 








  
 - 4 -


 
million, within 20 days thereof, the Company will make an Asset Sale Offer to all Holders of Notes and all holders of other Indebtedness that is pari passu with the Notes containing
provisions similar to those set forth in this Indenture with respect to offers to purchase or redeem with the proceeds of sales of assets in accordance with Section 3.11 hereof to purchase the maximum principal amount of Notes and such other
pari passu Indebtedness that may be purchased out of the Excess Proceeds. The offer price in any Asset Sale Offer will be equal to 100% of the principal amount plus accrued and unpaid interest, if any, to the date of purchase, and will be
payable in cash. If any Excess Proceeds remain after consummation of an Asset Sale Offer, the Company may use those Excess Proceeds for any purpose not otherwise prohibited by this Indenture. If the aggregate principal amount of Notes and other
pari passu Indebtedness tendered into such Asset Sale Offer exceeds the amount of Excess Proceeds, the Trustee will select the Notes and such other pari passu Indebtedness to be purchased on a pro rata basis. Upon completion of each
Asset Sale Offer, the amount of Excess Proceeds will be reset at zero.” 
  

	 	(xiv)	The words “$25.0 million” in the fifth paragraph of Section 4.10 of the FRN Indenture shall be deleted and replaced with the words “$5.0
million” in the New FRN Indenture; 

  

	 	(xv)	Section 9.02 of the FRN Indenture shall be amended by adding the following language as a new second paragraph thereto in the New FRN Indenture:


 “However, the consent of Holders of seventy-five percent (75%) in aggregate principal amount of the
then outstanding Notes (including without limitation, Additional Notes, if any) voting as a single class (including, without limitation, consents obtained in connection with a tender offer or exchange offer for, or purchase of, the Notes) shall be
required for any amendment, supplement or waiver under this Section 9.02 that amends, supplements, or waives the application of, as applicable, (i) the second subsection (1), subsection (6) or subsection (11) in the definition of
“Asset Sale” in Section 1.01 hereof; (ii) the definition of “LIBOR” in Section 1.01 hereof; (iii) the definition of “Net Proceeds” in Section 1.01 hereof; (iv) the second, fourth or fifth
paragraphs of Section 4.10 hereof; or (v) this paragraph.” 
  

	 	(xvi)	The schedule referred to in the second subsection (1) in the definition of “Asset Sale” in the New FRN Indenture shall contain the information set forth
in Schedule “E” of the Support Agreement. 

  

	 	B.	The attached Schedule “B” shall be added as Schedule “E” to the Support Agreement. 


 

	 	C.	Section 1 is amended by adding the following: 









  
 - 5 -



	 	(e)	the New Floating Rate Notes shall have the attributes described in the Exchange Offering Memorandum dated February 10, 2011, modified to reflect Subsection
(1)(a) of this Agreement. 

  

	 	D.	Section 4(c)(viii) shall be deleted and replaced with the following: 

 “not (A) object to, delay, impede or take any other action to interfere with the acceptance or implementation of the Exchange Transaction or the Recapitalization Transaction; (B) propose,
file, support or vote in favour of any alternative exchange offer, restructuring, workout or plan of compromise or arrangement or reorganization of or for the Companies; or (C) take any action, directly or indirectly, that is materially
inconsistent with, or is intended or is likely to interfere with the consummation of, the Exchange Transaction, except as required by applicable Law or by any stock exchange rules, by any other regulatory authority having jurisdiction over the
Consenting Noteholder or by any court of competent jurisdiction.” 
  

	 	E.	Section 4(d) shall be deleted and replaced with the following: 

 “Each Consenting Noteholder agrees to support the Recapitalization Transaction and execute a Waiver Letter in a form acceptable to the Trustee, pursuant to which the Consenting Noteholder agrees to
waive any and all “Defaults” and “Events of Default” (as defined in the FRN Indenture), and change of control, if any, that may arise as a result of the steps to implement or completion of the Recapitalization Transaction
pursuant to an exchange offer, plan of arrangement under the Canada Business Corporations Act (Canada) or any plan or proceedings under any insolvency proceeding or statute in Canada or the United States, including, without limitation, the
Companies’ Creditors Arrangement Act, or the United States Bankruptcy Code, and, if applicable, waive any cross-default under the FRN Indenture that may arise as a result of Angiotech’s failure to pay any interest or principal or
other payments that may be due and payable now or in the future under the Senior Subordinated Note Indenture and any event of default resulting from the filing by the Companies under the CCAA and Chapter 15 of the United States Bankruptcy Code
(collectively, the “Waiver Matters”). For greater certainty, nothing in this Agreement requires the Consenting Noteholders or any of them to indemnify the Trustee or any other Person in any manner whatsoever. As an alternative to
effecting the Exchange Terms by way of exchange offer, the Companies may complete the Exchange Transaction by way of (i) a plan under the Canada Business Corporations Act (Canada); (ii) any plan or proceedings under any insolvency
proceeding or statute in Canada or the United States, including, without limitation, the Companies’ Creditors Arrangement Act, or the United States Bankruptcy Code; or (iii) a consent solicitation and amendment to the FRN Indenture
(collectively, the “Alternative Transaction Structures”), and the Consenting Noteholder hereby consents to and agrees to vote in favour of the completion of the Exchange Transaction pursuant to any of the Alternative Transaction
Structures, provided that the Consenting Noteholder receives Floating Rate Notes that have the attributes of the New Floating Rate Notes as described in Section 1 hereof. Without limiting the generality of the foregoing, provided that,









  
 - 6 -


 
the Exchange Transaction results in the New Floating Rate Notes having the attributes described in the Exchange Offering Memorandum dated February 10, 2011, modified to reflect Subsection
(1)(a) of this Agreement, subject to the rights of the Sixth Amendment Consenting Noteholders under the Fee Undertaking, all Consenting Noteholders shall support, consent to and not oppose the position of the Company on any motion or other
proceeding in the Companies’ proceedings under the CCAA or Chapter 15 of the United States Bankruptcy Code or any other related proceeding, including the sanctioning of the Companies’ plan of arrangement to the extent the Company’s
position is supported by Consenting Noteholders holding not less than a majority of the aggregate principal amount of Floating Rate Notes subject to this Agreement.” 

 

	 	F.	Section 15(n) shall be deleted and replaced with the following: 

 “This Agreement may be modified, amended or supplemented as to any matter by an instrument in writing signed by the Companies and Consenting Noteholders that represent not less than a majority of the
Floating Rate Notes subject to this Agreement; provided, however, that this Agreement may not be modified, amended or supplemented as to any of the Sixth Amendment Terms, and none of the Sixth Amendment Terms shall be waived, in each case, without
the consent of the Consenting Noteholders holding not less than 75% of the aggregate principal amount of Floating Rate Notes subject to this Agreement.” 
  

	 	G.	Section 15(o) shall be deleted and replaced with the following: 

 “Notwithstanding anything to the contrary in Section 15(n) hereof, if this Agreement is amended, modified or supplemented or any matter herein is approved, consented to or waived: (i) in a
manner that materially adversely affects the consideration described in Section 1 hereof to be provided to Noteholders or (ii) such that the Outside Date is extended beyond October 15, 2011, then any Consenting Noteholder that objects
to any such amendment, modification, supplement, approval, consent or waiver of this Agreement may terminate its obligations under this Agreement upon five (5) Business Days’ written notice to the other Parties hereto (each, an
“Objecting Noteholder”) and shall thereupon no longer be a Consenting Noteholder; provided, further, that, in the event that the Fee Undertaking is breached by Angiotech, in each case, any of the Sixth Amendment Consenting
Noteholders may terminate its obligations under this Agreement upon five (5) Business Days’ written notice to the other Parties hereto and shall thereupon be considered an Objecting Noteholder and no longer be a Consenting Noteholder and
have all the rights it would have had as if it never became a party to this Agreement.” 
  

	 	H.	The following shall be added to the Support Agreement as a new Section 16: 

 “16. Releases 
  

	 	(a)	 On the Implementation Date, the Companies and each and every present and former shareholder, affiliate, subsidiary, director, officer, member
(including 










  
 - 7 -



	 	 
members of any committee or governance council), partner, employee, auditor, financial advisor, legal counsel and agent of any of the foregoing and any Person claiming to be liable derivatively
through any or all of the foregoing Persons (each in their capacity as such and being herein referred to individually as a “Non-FRN Released Party”) shall be released and discharged by the Consenting Noteholders from any and all
demands, claims, actions, causes of action, counterclaims, suits, debts, sums of money, accounts, covenants, damages, judgments, orders, including for injunctive relief or specific performance and compliance orders, expenses, executions,
encumbrances and other recoveries on account of any liability, obligation, demand or cause of action of whatever nature which any of the Companies’ creditors or other Person may be entitled to assert, including any and all claims in respect of
the payment and receipt of proceeds and statutory liabilities of present and former directors, officers, members and employees of the Companies and any alleged fiduciary or other duty (whether acting as a director, officer, member, employee or
acting in any other capacity), whether known or unknown, matured or unmatured, direct, indirect or derivative, foreseen or unforeseen, existing or hereafter arising, based in whole or in part on any omission, transaction, duty, responsibility,
indebtedness, liability, obligation, dealing or other occurrence existing or taking place on or prior to the later of the Implementation Date and the date on which actions are taken to implement the Exchange that are in any way relating to, arising
out of or in connection with the Floating Rate Notes, the FRN Indenture, the Support Agreement (together with all Amendments), the Fee Undertaking (so long as Angiotech has fully performed all of its obligations thereunder as of the Implementation
Date), any claims, the business and affairs of the Companies whenever or however conducted, the administration and/or management of the Companies, the Plan, the CCAA Proceeding, and all claims arising out of such actions or omissions shall be
forever waived and released (other than the right to enforce the Companies’ obligations under the Support Agreement (if any), the Plan, the New FRN Indenture or the New Floating Rate Notes and other than the right of the Sixth Amendment
Consenting Noteholders to enforce Angiotech’s obligations under the Fee Undertaking if such obligations have not been fully performed by Angiotech as of the Implementation Date), all to the full extent permitted by Law, provided that nothing
herein shall release or discharge any Released Party for criminal acts or omissions, fraud, gross negligence or other wilful misconduct or present or former directors of the Companies with respect to matters set out in section 5.1(2) of the CCAA.



  

	 	(b)	 On the Implementation Date, the Consenting Noteholders and each and every present and former shareholder, affiliate, subsidiary, director, officer,
member (including members of any committee or governance council), partner, employee, auditor, financial advisor, legal counsel and agent of any of the foregoing and any Person claiming to be liable derivatively through any or all of the foregoing
Persons (each in their capacity as such and being herein referred to individually as an “FRN Released Party”) shall be released and discharged by the Companies from any and all demands, claims, actions, causes of action,
counterclaims, suits, debts, sums of money, accounts, covenants, damages, judgments, orders, including for injunctive relief or specific performance and 










  
 - 8 -



	 	 
compliance orders, expenses, executions, encumbrances and other recoveries on account of any liability, obligation, demand or cause of action of whatever nature which any of the Non-FRN Released
Party or other Person may be entitled to assert, whether known or unknown, matured or unmatured, direct, indirect or derivative, foreseen or unforeseen, existing or hereafter arising, based in whole or in part on any omission, transaction, duty,
responsibility, indebtedness, liability, obligation, dealing or other occurrence existing or taking place on or prior to the later of the Implementation Date and the date on which actions are taken to implement the Exchange that are in any way
relating to, arising out of or in connection with the Floating Rate Notes, the FRN Indenture, the Support Agreement (together with all Amendments), the Fee Undertaking (so long as Angiotech has fully performed all of its obligations thereunder as of
the Implementation Date), any claims, the business and affairs of the Companies whenever or however conducted, the administration and/or management of the Companies, the Plan, the CCAA Proceeding, and all claims arising out of such actions or
omissions shall be forever waived and released (other than the right to enforce the Companies’ obligations under the Support Agreement (if any), the Plan, the New FRN Indenture or the New Floating Rate Notes and other than the right of the
Sixth Amendment Consenting Noteholders to enforce Angiotech’s obligations under the Fee Undertaking if such obligations have not been fully performed by Angiotech as of the Implementation Date), all to the full extent permitted by Law, provided
that nothing herein shall release or discharge any FRN Released Party for criminal acts or omissions, fraud, gross negligence or other wilful misconduct.” 



 

	 	I.	The following definitions shall be added to Schedule “B” of the Support Agreement: 


“Advisors” means Goodmans LLP, Houlihan Lokey, and Latham & Watkins LLP. 

“Blackstone” means The Blackstone Group LP. 
 “CCAA” means the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended. 
 “CCAA Proceeding” means the proceeding commenced by the Companies under the CCAA on the Order Date in the Supreme Court of British Columbia at Vancouver under No. S110587. 

“DIP Lender” shall have the meaning ascribed thereto in the Initial Order. 

“DIP Credit Agreement” means the credit agreement dated February 7, 2011 between the Companies, as borrowers and
guarantors, certain lenders signatory thereto and Wells Fargo, as arranger and administrative Agent. 








  
 - 9 -


 “Fee Undertaking” means that certain undertaking dated as of the date of
the Sixth Amendment executed by Angiotech in favour of the Sixth Amendment Consenting Noteholders. 
 “Initial
Order” means the order obtained by the Companies (as may be amended, restated or varied from time to time) made by the Honourable Justice Walker of the Supreme Court of British Columbia under the CCAA dated January 28, 2011.

 “Monitor” means Alvarez & Marsal Canada Inc., as Court-appointed Monitor in the CCAA Proceeding of
the Companies. 
 “Order” means any order of the Court made in connection with the CCAA Proceeding of the Plan.

 “Order Date” means January 28, 2011. 

“Plan” means the Plan of Compromise or Arrangement filed by the Companies under the CCAA, as such Plan may be amended,
supplemented or restated from time to time in accordance with the terms thereof. 
 “Released Party” shall have
the meaning ascribed thereto in Section 16 of this Agreement. 
 “Sanction Order” means the Order of the
Court sanctioning and approving the Plan. 
 “Sixth Amendment” means that certain amendment hereof dated as of
February 22, 2011. 
 “Sixth Amendment Consenting Noteholders” means those holders of Floating Rate Notes
that first executed a Consent Agreement as of the date of the Sixth Amendment. 
 “Sixth Amendment Terms” means
the amendatory language in respect of the Support Agreement set forth in subsections (A) through and including (H) of section 3 of the Sixth Amendment. 
 “Subordinated Note Indenture Trustee” means U.S. Bank National Association in its capacity as indenture trustee under the Subordinated Note Indenture and any duly appointed successor
indenture trustee thereunder. 
 “Wells Fargo” means Wells Fargo Capital Finance, LLC, in its capacity as agent
and lender under the Wells Fargo Credit Agreement and DIP lender under the DIP Credit Agreement. 
  

	 	J.	The following definitions in Schedule “B” of the Support Agreement are hereby amended deleted and replaced as follows: 









  
 - 10 -


 “Court” means the Ontario Superior Court of Justice or the Supreme Court of
British Columbia. 
 “Wells Fargo Credit Agreement” means the Credit Agreement dated as of February 27,
2009, as amended, between the Companies, as borrowers and guarantors, the lenders signatory thereto and Wells Fargo, as arranger and administrative agent as amended from time to time. 

 

	 	K.	The definition of “Wells Fargo Facility” is hereby deleted from Schedule “B” of the Support Agreement. 


 

	4.	Support Agreement to apply in full force and effect 

 Except as expressly modified by the terms of this Sixth Amendment, the terms and conditions of the Support Agreement shall continue to apply in full force and effect, unamended. 

 

	5.	Miscellaneous 

  

	 	(a)	This Sixth Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein,
without regard to principles of conflicts of law. Each of the parties to this Sixth Amendment submits to the jurisdiction of the courts of the Province of Ontario in any action or proceeding arising out of or relating to this Sixth Amendment.


  

	 	(b)	This Sixth Amendment may be signed in counterparts, each of which, when taken together, shall be deemed an original. Execution of this Sixth Amendment is effective if a
signature is delivered by facsimile transmission or electronic (e.g., pdf) transmission. 

  
 [The remainder of this page is intentionally left blank] 







 This Sixth Amendment has been agreed and accepted on the date first written above. 

 

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	 By:
	 	/s/ K. Thomas Bailey
		 	 Name:  K. Thomas Bailey

		 	 Title:    Chief Financial Officer

	
	 AFMEDICA, INC.;
 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.;
 ANGIOTECH AMERICA, INC.;

ANGIOTECH BIOCOATINGS CORP.;
 ANGIOTECH
DELAWARE, INC.; ANGIOTECH FLORIDA HOLDINGS, INC.;
 ANGIOTECH PHARMACEUTICALS (US), INC.;

B.G. SULZLE, INC.;
 MANAN MEDICAL
PRODUCTS, INC.;
 MEDICAL DEVICE TECHNOLOGIES, INC.;
 NEUCOLL, INC.;
 QUILL MEDICAL, INC.;

SURGICAL SPECIALTIES CORPORATION;

SURGICAL SPECIALTIES PUERTO RICO, INC.; and

SURGICAL SPECIALTIES UK HOLDINGS LIMITED

		
	 By:
	 	/s/ K. Thomas Bailey
		 	 Name:  K. Thomas Bailey

		 	 Title:    President










 
			
	ANGIOTECH INTERNATIONAL HOLDINGS CORP.; and
	
	0741693 B.C. LTD.
		
	 By:
	 	/s/ Jay Dent
		 	 Name:  Jay Dent

		 	 Title:    President